Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation

Daniel R. Couriel, Rima M. Saliba, Sergio Giralt, Issa Khouri, Borje Andersson, Marcos de Lima, Chitra Hosing, Paolo Anderlini, Michelle Donato, Karen Cleary, James Gajewski, Joyce Neumann, Cindy Ippoliti, Gabriela Rondon, Agueda Cohen, Richard Champlin

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

In this study, we evaluated the influence of nonmyeloablative and ablative conditioning regimens on the occurrence of acute and chronic graft-versus-host disease (GVHD). One hundred thirty-seven patients undergoing matched-related sibling transplantations received the same GVHD prophylaxis. Myeloablative regimens included intravenous busulfan/cyclophosphamide (n = 45) and fludarabine/melphalan (n = 29). Patients in the nonmyeloablative group (n = 63) received fludarabine/idarubicin/cytarabine, cisplatin/fludarabine/idarubicin, and fludarabine/cyclophosphamide. The actuarial rate of grade II to IV acute GVHD was significantly higher (hazard ratio, 3.6; 95% confidence interval, 1.5-8.8) in patients receiving ablative regimens (36%) compared with the nonmyeloablative group (12%). The cumulative incidence of chronic GVHD was higher in the ablative group (40%) compared with the nonmyeloablative group (14%). The rates were comparable within the first 200 days and were significantly higher in the ablative group beyond day 200 (hazard ratio, 5.2; 95% confidence interval, 1.2-23.2). Nonrelapse and GVHD-related mortality were relatively low in both groups. The use of the described nonmyeloablative preparative regimens was associated with a reduced incidence of grade II to IV acute GVHD and chronic GVHD compared with the busulfan/cyclophosphamide and fludarabine/melphalan transplant regimens. It is interesting to note that nonrelapse mortality with nonmyeloablative regimens in older and more debilitated patients was low (14%) and comparable to that achieved with standard high-dose regimens in younger patients

Original languageEnglish (US)
Pages (from-to)178-185
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume10
Issue number3
DOIs
StatePublished - Mar 2004
Externally publishedYes

Fingerprint

Homologous Transplantation
Graft vs Host Disease
Idarubicin
Cyclophosphamide
Busulfan
Melphalan
Confidence Intervals
Mortality
Cytarabine
Incidence
Conditioning (Psychology)
Cisplatin
Siblings
Transplantation
fludarabine
Transplants

Keywords

  • Acute GVHD
  • Preparative regimens

ASJC Scopus subject areas

  • Transplantation

Cite this

Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. / Couriel, Daniel R.; Saliba, Rima M.; Giralt, Sergio; Khouri, Issa; Andersson, Borje; de Lima, Marcos; Hosing, Chitra; Anderlini, Paolo; Donato, Michelle; Cleary, Karen; Gajewski, James; Neumann, Joyce; Ippoliti, Cindy; Rondon, Gabriela; Cohen, Agueda; Champlin, Richard.

In: Biology of Blood and Marrow Transplantation, Vol. 10, No. 3, 03.2004, p. 178-185.

Research output: Contribution to journalArticle

Couriel, DR, Saliba, RM, Giralt, S, Khouri, I, Andersson, B, de Lima, M, Hosing, C, Anderlini, P, Donato, M, Cleary, K, Gajewski, J, Neumann, J, Ippoliti, C, Rondon, G, Cohen, A & Champlin, R 2004, 'Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation', Biology of Blood and Marrow Transplantation, vol. 10, no. 3, pp. 178-185. https://doi.org/10.1016/j.bbmt.2003.10.006
Couriel, Daniel R. ; Saliba, Rima M. ; Giralt, Sergio ; Khouri, Issa ; Andersson, Borje ; de Lima, Marcos ; Hosing, Chitra ; Anderlini, Paolo ; Donato, Michelle ; Cleary, Karen ; Gajewski, James ; Neumann, Joyce ; Ippoliti, Cindy ; Rondon, Gabriela ; Cohen, Agueda ; Champlin, Richard. / Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. In: Biology of Blood and Marrow Transplantation. 2004 ; Vol. 10, No. 3. pp. 178-185.
@article{2940d4c389cb485c8dbeb33575d8820a,
title = "Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation",
abstract = "In this study, we evaluated the influence of nonmyeloablative and ablative conditioning regimens on the occurrence of acute and chronic graft-versus-host disease (GVHD). One hundred thirty-seven patients undergoing matched-related sibling transplantations received the same GVHD prophylaxis. Myeloablative regimens included intravenous busulfan/cyclophosphamide (n = 45) and fludarabine/melphalan (n = 29). Patients in the nonmyeloablative group (n = 63) received fludarabine/idarubicin/cytarabine, cisplatin/fludarabine/idarubicin, and fludarabine/cyclophosphamide. The actuarial rate of grade II to IV acute GVHD was significantly higher (hazard ratio, 3.6; 95{\%} confidence interval, 1.5-8.8) in patients receiving ablative regimens (36{\%}) compared with the nonmyeloablative group (12{\%}). The cumulative incidence of chronic GVHD was higher in the ablative group (40{\%}) compared with the nonmyeloablative group (14{\%}). The rates were comparable within the first 200 days and were significantly higher in the ablative group beyond day 200 (hazard ratio, 5.2; 95{\%} confidence interval, 1.2-23.2). Nonrelapse and GVHD-related mortality were relatively low in both groups. The use of the described nonmyeloablative preparative regimens was associated with a reduced incidence of grade II to IV acute GVHD and chronic GVHD compared with the busulfan/cyclophosphamide and fludarabine/melphalan transplant regimens. It is interesting to note that nonrelapse mortality with nonmyeloablative regimens in older and more debilitated patients was low (14{\%}) and comparable to that achieved with standard high-dose regimens in younger patients",
keywords = "Acute GVHD, Preparative regimens",
author = "Couriel, {Daniel R.} and Saliba, {Rima M.} and Sergio Giralt and Issa Khouri and Borje Andersson and {de Lima}, Marcos and Chitra Hosing and Paolo Anderlini and Michelle Donato and Karen Cleary and James Gajewski and Joyce Neumann and Cindy Ippoliti and Gabriela Rondon and Agueda Cohen and Richard Champlin",
year = "2004",
month = "3",
doi = "10.1016/j.bbmt.2003.10.006",
language = "English (US)",
volume = "10",
pages = "178--185",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation

AU - Couriel, Daniel R.

AU - Saliba, Rima M.

AU - Giralt, Sergio

AU - Khouri, Issa

AU - Andersson, Borje

AU - de Lima, Marcos

AU - Hosing, Chitra

AU - Anderlini, Paolo

AU - Donato, Michelle

AU - Cleary, Karen

AU - Gajewski, James

AU - Neumann, Joyce

AU - Ippoliti, Cindy

AU - Rondon, Gabriela

AU - Cohen, Agueda

AU - Champlin, Richard

PY - 2004/3

Y1 - 2004/3

N2 - In this study, we evaluated the influence of nonmyeloablative and ablative conditioning regimens on the occurrence of acute and chronic graft-versus-host disease (GVHD). One hundred thirty-seven patients undergoing matched-related sibling transplantations received the same GVHD prophylaxis. Myeloablative regimens included intravenous busulfan/cyclophosphamide (n = 45) and fludarabine/melphalan (n = 29). Patients in the nonmyeloablative group (n = 63) received fludarabine/idarubicin/cytarabine, cisplatin/fludarabine/idarubicin, and fludarabine/cyclophosphamide. The actuarial rate of grade II to IV acute GVHD was significantly higher (hazard ratio, 3.6; 95% confidence interval, 1.5-8.8) in patients receiving ablative regimens (36%) compared with the nonmyeloablative group (12%). The cumulative incidence of chronic GVHD was higher in the ablative group (40%) compared with the nonmyeloablative group (14%). The rates were comparable within the first 200 days and were significantly higher in the ablative group beyond day 200 (hazard ratio, 5.2; 95% confidence interval, 1.2-23.2). Nonrelapse and GVHD-related mortality were relatively low in both groups. The use of the described nonmyeloablative preparative regimens was associated with a reduced incidence of grade II to IV acute GVHD and chronic GVHD compared with the busulfan/cyclophosphamide and fludarabine/melphalan transplant regimens. It is interesting to note that nonrelapse mortality with nonmyeloablative regimens in older and more debilitated patients was low (14%) and comparable to that achieved with standard high-dose regimens in younger patients

AB - In this study, we evaluated the influence of nonmyeloablative and ablative conditioning regimens on the occurrence of acute and chronic graft-versus-host disease (GVHD). One hundred thirty-seven patients undergoing matched-related sibling transplantations received the same GVHD prophylaxis. Myeloablative regimens included intravenous busulfan/cyclophosphamide (n = 45) and fludarabine/melphalan (n = 29). Patients in the nonmyeloablative group (n = 63) received fludarabine/idarubicin/cytarabine, cisplatin/fludarabine/idarubicin, and fludarabine/cyclophosphamide. The actuarial rate of grade II to IV acute GVHD was significantly higher (hazard ratio, 3.6; 95% confidence interval, 1.5-8.8) in patients receiving ablative regimens (36%) compared with the nonmyeloablative group (12%). The cumulative incidence of chronic GVHD was higher in the ablative group (40%) compared with the nonmyeloablative group (14%). The rates were comparable within the first 200 days and were significantly higher in the ablative group beyond day 200 (hazard ratio, 5.2; 95% confidence interval, 1.2-23.2). Nonrelapse and GVHD-related mortality were relatively low in both groups. The use of the described nonmyeloablative preparative regimens was associated with a reduced incidence of grade II to IV acute GVHD and chronic GVHD compared with the busulfan/cyclophosphamide and fludarabine/melphalan transplant regimens. It is interesting to note that nonrelapse mortality with nonmyeloablative regimens in older and more debilitated patients was low (14%) and comparable to that achieved with standard high-dose regimens in younger patients

KW - Acute GVHD

KW - Preparative regimens

UR - http://www.scopus.com/inward/record.url?scp=10744226751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744226751&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2003.10.006

DO - 10.1016/j.bbmt.2003.10.006

M3 - Article

VL - 10

SP - 178

EP - 185

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 3

ER -